Galena Biopharma to Present at the Noble Financial Capital Markets 11th Annual Investor Conference
January 15 2015 - 7:05AM
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company
developing and commercializing innovative, targeted oncology
treatments that address major medical needs across the full
spectrum of cancer care, today announced that Mark W. Schwartz,
Ph.D., President and Chief Executive Officer will present a
corporate update at the Noble Financial Capital Markets 11th Annual
Investor Conference. The presentation will take place on Tuesday,
January 20, 2015 at 2:00 p.m. ET in Sandpiper Bay, Florida.
The presentation will be webcast and available on the Investors
section of the Company's website at www.galenabiopharma.com.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a biopharmaceutical
company developing and commercializing innovative, targeted
oncology therapeutics that address major medical needs across the
full spectrum of cancer care. Galena's development portfolio ranges
from mid- to late-stage clinical assets, including a robust
immunotherapy program led by NeuVax™ (nelipepimut-S) currently in
an international, Phase 3 clinical trial. The Company's commercial
drugs include Abstral® (fentanyl) Sublingual Tablets and Zuplenz®
(ondansetron) Oral Soluble Film. Collectively, Galena's clinical
and commercial strategy focuses on identifying and advancing
therapeutic opportunities to improve cancer care, from direct
treatment of the disease to the reduction of its debilitating
side-effects. For more information, visit
www.galenabiopharma.com.
CONTACT: Remy Bernarda
Vice President, Marketing & Communications
(503) 405-8258
rbernarda@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024